21:56 , Jul 23, 2019 |  BC Extra  |  Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
23:27 , Jul 1, 2019 |  BC Extra  |  Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

Alnylam submits hepatic porphyria therapy MAA  Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic...
14:41 , Mar 4, 2019 |  BC Extra  |  Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
01:30 , Mar 1, 2019 |  BC Week In Review  |  Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Feb. 27 after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation -...
19:36 , Feb 27, 2019 |  BC Extra  |  Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Wednesday after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC...
22:14 , Jan 31, 2019 |  BC Extra  |  Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

Janssen Pharmaceuticals Inc. picked up its first clinical gene therapies Thursday in a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx added $2.84 (30%) to $12.38 on Thursday....
19:51 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Sept. 27, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
21:25 , Sep 28, 2018 |  BC Extra  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
02:37 , Sep 14, 2018 |  BC Innovations  |  Product R&D

Academia’s manufacturing problem

With backups at academic manufacturing centers beginning to hamper translation of early stage gene therapies, pushing those who can afford it to CMOs, at least one non-profit has stepped in with a model to deliver...